Giant Fungated Locally Advanced Breast Carcinoma Responded to Hypofractionated Radiotherapy Combined with Apatinib: A Case Report and Literature Review

References

• Thakur V, Kutty RV. Recent advances in nanotheranostics for triple negative breast cancer treatment. J Exp Clin Cancer Res. 2019;38(1):430. doi:10.1186/s13046-019-1443-131661003
   PubMed Web of Science ®Google Scholar
• Gangi A, Chung A, Mirocha J, Liou DZ, Leong T, Giuliano AE. Breast-conserving therapy for triple-negative breast cancer. JAMA Surg. 2014;149(3):252–258. doi:10.1001/jamasurg.2013.303724382582
   PubMed Web of Science ®Google Scholar
• Hu X, Zhang J, Xu B, et al. Multicenter Phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135(8):1961–1969. doi:10.1002/ijc.2882924604288
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–10874. doi:10.1073/pnas.19136709811553815
   PubMed Web of Science ®Google Scholar
• Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9(1):29–33. doi:10.3816/CBC.2009.n.00519299237
   PubMed Web of Science ®Google Scholar
• Yee C, Alayed Y, Drost L, et al. Radiotherapy for patients with unresected locally advanced breast cancer. Ann Palliat Med. 2018;7(4):373–384. doi:10.21037/apm.2018.05.1330180725
   PubMed Web of Science ®Google Scholar
• Coelho RC, Da Silva FML, Do Carmo IML, Bonaccorsi BV, Hahn SM, Faroni LD. Is there a role for salvage radiotherapy in locally advanced breast cancer refractory to neoadjuvant chemotherapy? Breast. 2017;31:192–196. doi:10.1016/j.breast.2016.10.02627889595
   PubMed Web of Science ®Google Scholar
• Kosma L, Koukourakis M, Skarlatos J, et al. Hypofractionated radiotherapy with 5-fluorouracil radiosensitization for locally “far advanced” breast cancer. Am J Clin Oncol. 1997;20(6):562–566. doi:10.1097/00000421-199712000-000059391540
   PubMed Web of Science ®Google Scholar
• Ghiam AF, Spayne J, Lee J. Current challenges and future perspectives of radiotherapy for locally advanced breast cancer. Curr Opin Support Palliat Care. 2014;8(1):46–52. doi:10.1097/SPC.000000000000003224441684
   PubMed Web of Science ®Google Scholar
• Moran MS. Radiation therapy in the locoregional treatment of triple-negative breast cancer. Lancet Oncol. 2015;16(3):e113–122. doi:10.1016/S1470-2045(14)71104-025752562
   PubMed Web of Science ®Google Scholar
• Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish breast cancer cooperative group. J Clin Oncol. 2008;26(9):1419–1426. doi:10.1200/JCO.2007.14.556518285604
   PubMed Web of Science ®Google Scholar
• Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–1716.22019144
   PubMed Web of Science ®Google Scholar
• Zhang H, Wan C, Huang J, et al. In vitro radiobiological advantages of hypofractionation compared with conventional fractionation: early-passage NSCLC cells are less aggressive after hypofractionation. Radiat Res. 2018;190(6):584–595. doi:10.1667/RR14951.130234458
   PubMed Web of Science ®Google Scholar
• Lu HM, Zhang MW, Niu LM, Zeng HA, Yan M. [Clinical observation of apatinib mesylate for the treatment of multi- drug resistant advanced breast cancer]. Zhonghua Yi Xue Za Zhi. 2018;98(16):1246– 1249. doi:10.3760/cma.j.issn.0376-2491.2018.16.012.Chinese29747313
   PubMedGoogle Scholar
• Gao Z, Shi M, Wang Y, Chen J, Ou Y. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2. Pathol Res Pract. 2019;215(7):152422. doi:10.1016/j.prp.2019.04.01431079851
   PubMed Web of Science ®Google Scholar
• Mortezaee K, Parwaie W, Motevaseli E, et al. Targets for improving tumor response to radiotherapy. Int Immunopharmacol. 2019;76:105847. doi:10.1016/j.intimp.2019.10584731466051
   PubMed Web of Science ®Google Scholar
• Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN TM; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts. Br J Radiol. 2008;81(No special_issue_1):S21–27. doi:10.1259/bjr/5985397618819995
   PubMed Web of Science ®Google Scholar
• Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6(10):569–579. doi:10.1038/nrclinonc.2009.13019736552
   PubMed Web of Science ®Google Scholar
• Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19(10):2003–2012. doi:10.1016/j.cellsig.2007.05.01317658244
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62. doi:10.1126/science.110481915637262
   PubMed Web of Science ®Google Scholar
• Luo CW, Wu CC, Ch’ang HJ. Radiation sensitization of tumor cells induced by shear stress: the roles of integrins and FAK. Biochim Biophys Acta. 2014;1843(9):2129–2137. doi:10.1016/j.bbamcr.2014.06.00724946134
   PubMed Web of Science ®Google Scholar
• Ma J, Chen CS, Blute T, Waxman DJ. Antiangiogenesis enhances intratumoral drug retention. Cancer Res. 2011;71(7):2675–2685. doi:10.1158/0008-5472.CAN-10-324221447737
   PubMed Web of Science ®Google Scholar
• Liu M, Li H, Wang X, Jing L, Jiang P, Li Y. Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients. Cancer Med. 2020;9(8):2660–2673. doi:10.1002/cam4.292332073228
   PubMed Web of Science ®Google Scholar
• Akiki M, Haddad FG, Kourie HR, Khaddage A, Smayra VT. PD-L1 an unavoidable biomarker in advanced triple-negative breast cancer. Biomark Med. 2019;13(18):1539–1541. doi:10.2217/bmm-2019-034431631684
   PubMed Web of Science ®Google Scholar
• Razazan A, Behravan J. Single peptides and combination modalities for triple negative breast cancer. J Cell Physiol. 2020;235(5):4089–4108. doi:10.1002/jcp.2930031642059
   PubMed Web of Science ®Google Scholar
• Dolgin E. Atezolizumab Combo Approved for PD-L1-positive TNBC. Cancer Discov. 2019;9(5):OF2. doi:10.1158/2159-8290.CD-NB2019-038
   Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. doi:10.1056/NEJMoa180961530345906
   PubMed Web of Science ®Google Scholar
• Kim KW, Jeong JU, Lee KH, et al. Combined NK cell therapy and radiotherapy exhibit long-term therapeutic and anti-metastatic effects in a human triple negative breast cancer model. Int J Radiat Oncol Biol Phys. 2020;108(1):115–125. doi:10.1016/j.ijrobp.2019.09.04131605787
   PubMed Web of Science ®Google Scholar
• Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3):428–440.e5. doi:10.1016/j.ccell.2019.02.00130853353
   PubMed Web of Science ®Google Scholar